Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Rutgers Cancer Institute Investigator Aims to Lay Foundation for New Class of Anti Cancer Therapies

4/15/2016

0 Comments

 
​New Brunswick, NJ ― Rutgers Cancer Institute of New Jersey researcher and surgical oncologist Darren R. Carpizo, MD, PhD, has been awarded a $1,839,863 grant (R01-CA200800) from the National Cancer Institute to build upon research from his laboratory examining a drug compound that restores tumor suppressor function in the most commonly mutated gene in human cancer — the p53 gene.
 
The aim is to provide the foundation for the development of a new class of anti-cancer drugs that will target p53, resulting in broad activity against all cancer types.
 
The p53 gene is known as the “guardian of the human genome” in that it recognizes cellular stress and stops cell proliferation by either allowing the cell to recover from the stress or activating a protein that induces a program to kill the cell if the damage can’t be repaired.
 
The loss of this function can result in cancer cells escaping a controlled environment and multiplying throughout the body.
​Previous research by Dr. Carpizo’s laboratory identified a drug compound that restores tumor suppressor function by targeting a common p53 mutation known as p53-R175H. This mutant is non-functional, as it fails to bind to zinc which is required for the p53 protein to maintain a normal, physical structure and function properly. 
 
The drug compound, which Carpizo’s team previously tested on human cell lines in the laboratory, has been found to restore structure and function to the p53 mutant protein by restoring zinc binding as well as activating a program that selectively kills cancer cells with the p53-R175H mutation while leaving normal cells undisturbed. 
 
The mechanism of action which Carpizo and colleagues have termed “zinc metallochaperones” is novel.
 
“Pharmacologic restoration of the normal structure and function of a mutant protein with a zinc binding defect is unprecedented in drug development.  Reactivating mutant p53 with a drug has been one of the ‘holy grails’ of anti-cancer drug development,” notes Dr. Carpizo, who is an associate professor of surgery and pharmacology at Rutgers Robert Wood Johnson Medical School.
 
In this next phase of research, Carpizo and colleagues aim to further study the mechanism of action of zinc metallochaperones by investigating the mechanisms that cells use to respond to increases in zinc levels. 
 
They also will investigate the spectrum of p53 mutants (besides the p53-R175H) that are zinc binding impaired as this will increase the potential pool of patients that could theoretically benefit from zinc metallochaperones. 
 
Lastly, they will be investigating other compounds that function as zinc metallochaperones.
 
Along with Carpizo’s laboratory, the laboratories of Stewart Loh, PhD, at SUNY Upstate Medical University and Rutgers Cancer Institute Associate Member David Augeri, PhD, from Rutgers Translational Sciences at Rutgers University are collaborating on the work.
 
The project period runs through February 2021.
 
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center.  As part of Rutgers, The State University of New Jersey, the Cancer Institute of New Jersey is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention.  Physician-scientists at the Cancer Institute engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. 
 
The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community.  Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Affiliate Hospitals: JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), and Robert Wood Johnson University Hospital Somerset.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507